Extracorporeal perfusion apparatus

Patent metadata

Field	Value
Publication number	US-9861735-B2
Application number	US-201314411665-A
Country	US
Kind code	B2
Filing date	Jun 27, 2013
Priority date	Jun 28, 2012
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Embodiments of the invention relate to an extracorporeal perfusion apparatus comprising an extracorporeal blood circuit for conveying blood, a filtrate circuit for conveying blood plasma, and a controller, wherein the filtrate circuit is connected to the extracorporeal blood circuit by means of a filter, wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g/mol (relative molecular mass of 340 kDa), and wherein a depletion agent comprising a first carrier having a neutral, hydrophobic surface is arranged in the filtrate circuit, wherein the perfusion apparatus comprises a dispensing means for feeding an endotoxin-binding lipopeptide into the extracorporeal blood circuit, wherein the endotoxin-binding lipopeptide is selected from the group consisting of polymyxins, polymyxin derivatives, prodrugs thereof, and a combination thereof.

First claim

The invention claimed is:

1. An extracorporeal perfusion apparatus comprising an extracorporeal blood circuit for conveying blood, a filtrate circuit for conveying blood plasma, and a controller,
wherein the filtrate circuit is connected to the extracorporeal blood circuit via a filter, wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g/mol (relative molecular mass of 340 kDa), and
wherein a depletion agent comprising a first carrier having a neutral, hydrophobic surface is arranged in the filtrate circuit, and
wherein the extracorporeal perfusion apparatus comprises a dispenser provided separately from the filter for feeding an endotoxin-binding lipopeptide into the extracorporeal blood circuit, wherein the endotoxin-binding lipopeptide is selected from the group consisting of polymyxins, polymyxin derivatives, prodrugs thereof, and a combination thereof.

2. The extracorporeal perfusion apparatus according to claim 1 , wherein the endotoxin-binding lipopeptide is a polymyxin selected from the group consisting of polymyxin B, Colistin, and prodrugs thereof.

3. The extracorporeal perfusion apparatus according to claim 1 , wherein the depletion agent comprises the dispenser configured to feed the endotoxin-binding lipopeptide, wherein the surface of the first carrier has an adsorptive coating formed of the endotoxin-binding lipopeptide.

4. The extracorporeal perfusion apparatus according to claim 3 , wherein the endotoxin-binding lipopeptide adsorbed at the surface of the first carrier is present in a quantity that, when the lipopeptide is fed, gives a lipopeptide serum concentration from 0.01 μg/ml to 0.8 μg/ml.

5. The extracorporeal perfusion apparatus according to claim 3 , wherein the first carrier has a total surface from 100 to 1500 m 2 /g, wherein 50 to 2000 mg of endotoxin-binding lipopeptide in relation to the total carrier surface are bonded adsorptively at the surface of the first or second carrier.

6. The extracorporeal perfusion apparatus according to claim 3 , wherein the filtrate circuit leads into the filter, and in that the first carrier has the form of microparticles and the filtrate circuit comprises a suspension of these microparticles, wherein the microparticles have a mean particle size of 20 μm or smaller.

7. The extracorporeal perfusion apparatus according to claim 1 , wherein the dispenser configured to feed the endotoxin-binding lipopeptide is arranged in the filtrate circuit downstream of the depletion agent, wherein the dispenser comprises a second carrier having a neutral, hydrophobic surface, wherein the surface of the second carrier has an adsorptive coating formed of the endotoxin-binding lipopeptide.

8. The extracorporeal perfusion apparatus according to claim 1 , wherein the dispenser configured to feed the endotoxin-binding lipopeptide comprises a dosing device for feeding the endotoxin-binding lipopeptide into the extracorporeal blood circuit at a lipopeptide feed point associated with the extracorporeal blood circuit.

9. The extracorporeal perfusion apparatus according to claim 8 , wherein the lipopeptide feed point is arranged in the extracorporeal blood circuit downstream of the filter.

10. The extracorporeal perfusion apparatus according to claim 9 , wherein a dialyser is arranged in the extracorporeal blood circuit downstream of the filter, wherein the lipopeptide feed point is arranged in the extracorporeal blood circuit downstream of the dialyser.

11. The extracorporeal perfusion apparatus according to claim 9 , wherein a sensor configured to measure the concentration of the endotoxin-binding lipopeptide is arranged downstream of the filter or of the dialyser and upstream of the lipopeptide feed point.

12. The extracorporeal perfusion apparatus according to claim 8 , wherein the controller of the perfusion apparatus is configured, when the lipopeptide is dosed into the blood conveyed in the extracorporeal blood circuit, to take into consideration the lipopeptide clearance of the body, the lipopeptide clearance of the depletion agent and/or the lipopeptide clearance of the dialyser.

13. The extracorporeal perfusion apparatus according to claim 1 , wherein the dispenser configured to feed the endotoxin-binding lipopeptide comprises a dialyser arranged in the extracorporeal blood circuit downstream of the filter, said dialyser being configured to supply the endotoxin-binding lipopeptide to the extracorporeal blood circuit using a dialysis fluid conveyed through the dialyser.

14. The extracorporeal perfusion apparatus according to claim 1 , wherein the first carrier is formed from a neutral polymer.

15. The extracorporeal perfusion apparatus according to claim 14 , wherein the polymer is selected from a cross-linked polystyrene polymer or a cross-linked ethylene divinylbenzene polymer.

16. The extracorporeal perfusion apparatus according to claim 1 , wherein the first carrier is porous and has a mean pore size of 100 nm or less.

17. The extracorporeal perfusion apparatus according to claim 16 , wherein the first carrier has a mean pore size of 20 nm or less or a mean pore size from 80 to 100 nm.

18. The extracorporeal perfusion apparatus according to claim 1 , wherein the first carrier is fibre-like or is in particle form.

19. The extracorporeal perfusion apparatus according to claim 18 , wherein the first carrier has the form of microparticles having a mean particle size of 300 μm or smaller.

20. The extracorporeal perfusion apparatus according to claim 19 , wherein the first carrier has a mean pore size from one of either 10 nm to 20 nm or 80 nm to 100 nm and a mean particle size from 75 to 150 μm.

Assignees

• Fresenius Medical Care Deutschland Gmbh

Inventors

• Falkenhagen Dieter
• Hartmann Jens
• Harm Stephan

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61M2205/75

  with filters · CPC title

• B01J20/264

  derived from different types of monomers, e.g. linear or branched copolymers, block copolymers, graft copolymers · CPC title